Press Releases

Date Title and Summary Additional Formats
Toggle Summary Cellectar Announces Updated Median Overall Survival of 26.2 Months from Cohort 1 of CLR 131 Phase 1 Trial in Advanced Multiple Myeloma
MADISON, Wis., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the "company"), today announces that the ongoing median overall survival (mOS) from Cohort 1 of the Phase 1 study of its lead PDC™ compound, CLR 131
View HTML
Toggle Summary Cellectar Biosciences to Host Conference Call on November 10, 2017 to Report Third Quarter 2017 Financial Results and Corporate Performance
MADISON, Wis., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), (the "company"), an oncology-focused, clinical stage biotechnology company, today announces that management will host a teleconference and live webcast to report third quarter 2017 financial results,
View HTML
Toggle Summary New Preclinical Data Suggest That Cellectar Biosciences' PDC Platform Provides Enhanced Outcomes in Combination with External Radiation
MADISON, Wis., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the "company"), an oncology-focused, clinical stage biotechnology company, today announces data demonstrating that the company's phospholipid ether delivery vehicle conjugated to a non-reactive iodine
View HTML
Toggle Summary Cellectar Biosciences Introduces Multiple Dose Regimen in Fifth Cohort of Phase 1 Trial of CLR 131 in Multiple Myeloma
MADISON, Wis., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the "company"), today announces the design of the multiple dose fifth cohort of its Phase I dose escalation safety trial of lead PDC™ compound, CLR
View HTML
Toggle Summary Cellectar Biosciences Receives Additional Japanese Patent for CLR 131 and CLR 125 for the Treatment of Various Solid Tumors
MADISON, Wis., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the "company"), an oncology-focused, clinical stage biotechnology company, today announces the Japanese Patent Office has granted it a patent covering both composition of matter and method of use for CLR 131
View HTML
Toggle Summary Cellectar Biosciences Announces Successful Completion of $7.76 Million Registered Direct Offering
MADISON, Wis., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) ("Cellectar" or the "Company"), an oncology-focused biotechnology company, today announces the closing of its registered direct offering, priced at-the-market, of 1,954,388 shares of its common stock and
View HTML
Toggle Summary Cellectar Biosciences Announces $7.76 Million Registered Direct Offering Priced At-The-Market
MADISON, Wis., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB) ("Cellectar" or the "Company"), an oncology-focused biotechnology company, today announced that it entered into securities purchase agreements with certain institutional investors in connection with a
View HTML
Toggle Summary Cellectar Biosciences and Pierre Fabre Extend Collaboration for Development of New Phospholipid Drug Conjugates
MADISON, Wis. and CASTRES, France, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the "company"), together with leading French pharmaceutical company Pierre Fabre, today announce the extension of their ongoing
View HTML
Toggle Summary Cellectar Biosciences to Present at The MicroCap Conference
MADISON, Wis., Sept. 29, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused biotechnology company (the "company"), today announced that president and CEO Jim Caruso will present and meet with investors at The MicroCap Conference on Thursday, October 5 th at
View HTML
Toggle Summary Cellectar Biosciences Reports Cohort Four Data and Partial Response in Relapsed or Refractory Multiple Myeloma Patient Treated with CLR 131
MADISON, Wis., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the "company"), today announces that a patient treated with the company's lead PDC™ compound, CLR 131 in the fourth cohort of its Phase I dose
View HTML